A new study by Canadian researchers supports the safety of continued perioperative Glucagon-like peptide-1 receptor agonist (GLP-1RA) use in “patients meeting strict institutional pre-procedure screening pathways for short-duration ophthalmic surgeries under MMS [Mild-To-Moderate Sedation] in an ambulatory setting.” However, the researchers caution that their findings “may not extend to higher…
With the explosion of GLP-1–based therapies for type 2 diabetes and weight loss, perioperative nursing teams, especially in the preoperative and postanesthesia care areas, need to be fluent in recognizing these medications. Some patients may arrive on these agents—or even novel oral GLP-1s—and the physiologic effects, especially delayed gastric emptying,…
Editor's Note Glucagon-like peptide-1 (GLP-1) receptor agonists may offer orthopedic patients with obesity and type 2 diabetes a powerful tool for preoperative weight loss and potential disease modification, according to a July 10 review article in The Journal of Bone and Joint Surgery. However, the agents carry perioperative risks that…
